Search

Your search keyword '"E.M. Vida Navas"' showing total 7 results
Start Over Author "E.M. Vida Navas" Search Limiters Full Text
7 results on '"E.M. Vida Navas"'

1. 1117P Mutational landscape of large cell neuroendocrine lung carcinoma: Molecular characterization using next generation sequencing

Author

J.J. Soto-Castillo, V. Albarrán Fernández, Aguilera Gómez, Javier Pozas, J. Chamorro-Pérez, Jorge Esteban-Villarrubia, L. Sanz-Gómez, P. Alvarez-Ballesteros, D.I. Rosero-Rodríguez, Javier Torres-Jiménez, Y. Lage, I. Orejana-Martín, P. Garrido Lopez, Maria Eugenia Olmedo Garcia, E. Corral de la Fuente, A. Benito Berlinches, E.M. Vida-Navas, and M. San Roman-Gil

Subjects
Lung, medicine.anatomical_structure, Oncology, business.industry, Large cell, Carcinoma, medicine, Hematology, Computational biology, medicine.disease, business, DNA sequencing
Published
2021

2. 1744P COVID-19 in cancer patients: Risk factors for the development of severe clinical event (SCE)

Author

E.M. Vida Navas, P. Álvarez Ballesteros, R. Martín Huertas, M. San Román Gil, L. Sanz Gómez, P. Garrido Lopez, J. Esteban Villarrubia, A. Carrato Mena, E. Corral de la Fuente, J.J. Soto Castillo, J. Torres Jiménez, J. Serrano Domingo, I. Orejana Martin, and J. Pozas Pérez

Subjects
myalgia, Mechanical ventilation, medicine.medical_specialty, business.industry, medicine.medical_treatment, Cancer, Retrospective cohort study, Disease, Hematology, medicine.disease, Intensive care unit, Article, law.invention, Oncology, law, Internal medicine, Medicine, medicine.symptom, business, Lung cancer, Body mass index
Abstract

Background: Some studies have suggested a higher risk of respiratory complications related to COVID-19 (C-19) in cancer patients (pts), but there is a lack of knowledge concerning the outcomes and prognostic factors We evaluated whether various factors can predict a more serious C-19 infection Methods: We conducted a retrospective study including 51 pts diagnosed of C-19 between March 10 and April 7, 2020 All pts present tumor disease at diagnosis of C-19: advanced disease, neoadjuvant treatment (ttm) or maintenance ttm after definitive chemoradiotherapy It has been evaluated whether certain factors may present an increased risk for the development of a SCE, defined as death, the need of high oxygen flow (FiO2≥50%), non-invasive or invasive mechanical ventilation or Intensive Care Unit admission These factors have been age, ECOG, ttm line, type of ttm, time from last ttm to C-19 diagnosis, smoke, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, cardiopathy, body mass index, fever, cough, dyspnea, myalgia, gastrointestinal symptoms, infiltrates in chest radiography, CURB65 ≥1, creatine phosphokinase, lactate dehydrogenase and D-Dimer elevated, lymphopenia and PaO2/FiO2

Published
2020
Full Text
View/download PDF

3. 125P Benefit of immunotherapy in advanced NSCLC patients selected by KRAS mutations: A single institute retrospective analysis

Author

Y. Lage, L. Sanz Gómez, E.M. Vida Navas, J.J. Soto Castillo, E. Corral de la Fuente, M.E. Olmedo García, A. Gómez Rueda, M. Lario, and P. Garrido Lopez

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, medicine.medical_treatment, Internal medicine, Retrospective analysis, Medicine, KRAS, Immunotherapy, business, medicine.disease_cause
Published
2021

4. 52P Genetic and clinical profiling of a cohort of extended small cell lung carcinoma

Author

M.E. Olmedo García, J.J. Soto Castillo, Y. Lage, V. Albarrán Fernández, M. San Román Gil, P. Álvarez Ballesteros, J. Pozas Pérez, J. Esteban Villarrubia, M. Lario, L. Sanz Gómez, A. Caminoa Lizarralde, J. Chamorro Pérez, E.M. Vida Navas, P. Garrido Lopez, J. Torres Jiménez, D.I. Rosero Rodríguez, E. Corral de la Fuente, and A. Gómez Rueda

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Internal medicine, Cohort, medicine, Profiling (information science), Small Cell Lung Carcinoma, business
Published
2021

5. 6P Clinical and molecular characteristics in non-small cell lung cancer patients with alteration in PIK3 pathway

Author

A. Gómez Rueda, M.E. Olmedo García, M. Lario, A. Benito Berlinches, P. Álvarez Ballesteros, E. Corral de la Fuente, Y. Lage, A. Santón, J.J. Soto Castillo, J. Torres Jiménez, P. Garrido Lopez, and E.M. Vida Navas

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Cancer research, medicine, Non small cell, Lung cancer, medicine.disease, business
Published
2021

6. 218P Clinical characteristics and treatment outcomes in lung cancer patients with FGFR genes alterations

Author

A. Benito Berlinches, P. Garrido Lopez, P. Álvarez Ballesteros, M. Lario, J. Torres Jiménez, Y. Lage, M. San Román Gil, J. Esteban Villarrubia, D.I. Rosero Rodríguez, J. Chamorro Pérez, J. Pozas Pérez, V. Albarrán Fernández, L. Sanz Gómez, A. Santón, J.J. Soto Castillo, I. Orejana Martin, E.M. Vida Navas, A. Gómez Rueda, E. Corral de la Fuente, and M.E. Olmedo García

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Fibroblast growth factor receptor, business.industry, Internal medicine, Treatment outcome, medicine, Lung cancer, medicine.disease, business, Gene
Published
2021

7. 124P KRAS mutated (mt) non-small cell lung cancer (NSCLC) and response to antiPD-1/PD-L1 regarding co-mutational status and assessment of KRAS mutation on plasma or tissue biopsy

Author

A. Benito Berlinches, P. Álvarez Ballesteros, E.M. Vida Navas, Y. Lage, M.E. Olmedo García, J.J. Soto Castillo, E. Corral de la Fuente, A. Gómez Rueda, M. Lario, J. Torres Jiménez, and P. Garrido Lopez

Subjects
Pulmonary and Respiratory Medicine, biology, business.industry, non-small cell lung cancer (NSCLC), medicine.disease, medicine.disease_cause, Oncology, PD-L1, medicine, biology.protein, Cancer research, Mutational status, KRAS, business, Kras mutation, Tissue biopsy
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results